Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Pre-clinical results show poziotinib could potentially be effective in
patients with non-small cell lung cancer with EGFR exon 20 mutations.
Computational modeling suggests that due to its small size, poziotinib
may overcome the steric hindrance of the drug binding pocket.
An investigator sponsored clinical trial testing poziotinib in EGFR
exon 20 mutant non-small cell lung cancer patients is expected to
begin enrollment soon to investigate this hypothesis.
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in Hematology and Oncology announced the oral presentation
of data from a preclinical study evaluating poziotinib in lung cancer by
scientists from MD Anderson Cancer Center at the 17th International
Association for the Study of Lung Cancer (IASLC) World Conference on
Lung Cancer which took place in Vienna, Austria, December 4-7, 2016.
"We are honored to have an oral presentation on poziotinib presented at
the 17th IASLC World Conference," said Rajesh C. Shrotriya, MD, Chairman
and Chief Executive Officer of Spectrum Pharmaceuticals. "These results
show that poziotinib may work in a subset of non-small cell lung cancer
patients that have exon-20 mutations. Tumors with exon-20 mutations have
generally not been responsive to several other EGFR inhibitors. However,
due to its smaller size poziotinib is hypothesized to inhibit cell
growth of EGFR exon 20 insertions. These early results are very
encouraging and have the potential to be a transforming therapy for
patients who have little or no options and poor prognosis with median
progression free survival of 1.5 months. We are working closely with the
team at MD Anderson Cancer Center in expediting this research and
evaluating ways of serving the unmet medical need in this area."
Abstract/Oral Presentation #6203: Drug Repurposing to Overcome De
Novo Resistance of Non-Traditional EGFR Mutations: Poziotinib inhibits
EGFR exon 20 insertion mutations in NSCLC
EGFR exon 20 insertions induce a shift in the structure of cancer cells
that prevents binding of many EGFR inhibitors. In vitro, Ba/F3
cells with EGFR exon 20 insertions were screened against several EGFR
inhibitors including erlotinib, gefitinib, afatinib, dacomitinib,
neratinib, poziotinib, ibrutinib rocilentinib, EGF816, and osimertinib.
In Ba/F3 cells with EGFR exon 20 insertions, most of the TKIs failed to
inhibit growth of EGFR exon 20 insertions with IC50 values above 100nM.
However, poziotinib significantly inhibited cell growth of all EGFR exon
20 insertions tested with an average IC50 value of 2.9nM, as compared to
osimertinib and rocilentinib (IC50 values =103nM and 850nM,
respectively). In vivo, poziotinib reduced ≥80% of tumor
burden in multiple mouse models. Computational modeling suggests that
its smaller structure gives poziotinib the potential to overcome the
steric hindrance of the drug binding pocket. An investigator sponsored
clinical trial testing poziotinib in EGFR exon 20 mutant NSCLC patients
is expected to begin enrollment soon.
Poziotinib is a novel, oral pan-HER inhibitor that irreversibly blocks
signaling through the Epidermal Growth Factor Receptor (EGFR, HER)
Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2
(erbB2), and HER4 (erbB4), and importantly, also HER receptor mutations;
this, in turn, leads to the inhibition of the proliferation of tumor
cells that overexpress these receptors. Mutations or
overexpression/amplification of EGFR family receptors have been
associated with a number of different cancers, including non-small cell
lung cancer (NSCLC), breast cancer, and gastric cancer. Currently,
Poziotinib is being investigated by Hanmi in several mid-stage trials in
different solid tumor indications including HER2-positive breast cancer.
(Phase 2 sponsored by National OncoVenture, a funding initiative by the
Korean government's National Cancer Center).
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in Hematology and Oncology. Spectrum currently markets six
hematology/oncology drugs, and has an advanced stage pipeline that has
the potential to transform the Company. Spectrum's strong track record
for in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase 3
studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially. These
statements are based on management's current beliefs and expectations.
These statements include, but are not limited to, statements that
relate to Spectrum's business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, the timing and results of FDA decisions, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact. Risks that could cause actual results to differ include the
possibility that Spectrum's existing and new drug candidates may not
prove safe or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not receive
approval in a timely manner or at all, the possibility that our existing
and new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that our
efforts to acquire or in-license and develop additional drug candidates
may fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks that are
described in further detail in the Company's reports filed with the
Securities and Exchange Commission. The Company does not plan to
update any such forward-looking statements and expressly disclaims any
duty to update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a
registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source version on businesswire.com: http://www.businesswire.com/news/home/20161208005330/en/
Spectrum Pharmaceuticals, Inc.
Strategic Planning & Investor Relations
Source: Spectrum Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top